Elutia Inc.
$ 1.04
-0.95%
14 May - close price
- Market Cap 48,887,500 USD
- Current Price $ 1.04
- High / Low $ 1.07 / 1.03
- Stock P/E N/A
- Book Value 0.65
- EPS -0.64
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE N/A %
- 52 Week High 2.64
- 52 Week Low 0.50
About
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-04 | 2025-11-06 | 2025-08-14 | 2025-05-07 | 2025-03-05 | 2024-11-14 | 2024-08-07 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-14 |
| Reported EPS | 0 | 1.48 | -0.19 | -0.26 | -0.21 | -0.26 | 0.33 | -1.13 | -0.75 | -0.4 | -0.57 | -0.65 |
| Estimated EPS | -0.12 | -0.12 | -0.15 | -0.19 | -0.205 | -0.25 | -0.44 | -0.33 | -0.41 | -0.28 | -0.53 | -0.29 |
| Surprise | 0.12 | 1.6 | -0.04 | -0.07 | -0.005 | -0.01 | 0.77 | -0.8 | -0.34 | -0.12 | -0.04 | -0.36 |
| Surprise Percentage | 100% | 1333.3333% | -26.6667% | -36.8421% | -2.439% | -4% | 175% | -242.4242% | -82.9268% | -42.8571% | -7.5472% | -124.1379% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELUT
2026-05-14 20:09:04
Elutia Inc. (NASDAQ: ELUT) reported a wider net loss of $7.5 million in Q1 2026, despite slightly higher revenue of $3.1 million, as the company continues to invest in its drug-eluting biomatrix platform. Gross margins improved significantly, with GAAP at 57.9% and adjusted at 66.5%, driven by automated manufacturing for its NXT-41x product, which is targeting the breast reconstruction market. The company is advancing regulatory reviews for NXT-41 and NXT-41x, with anticipated FDA clearances in Q4 2026 and H1 2027, respectively, and is exploring divestitures for SimpliDerm and its Cardiovascular product line.
2026-04-22 21:09:26
Elutia Inc. (NASDAQ: ELUT) is asking stockholders to approve several proposals at its annual meeting on June 11, 2026. Key items include the re-election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the 2026 auditor, and an amendment to the 2020 Incentive Award Plan to increase share authorization, extend the annual "evergreen" share increase, and move the plan's termination date. The company also seeks advisory votes on executive compensation and the frequency of future say-on-pay votes, emphasizing the importance of equity compensation for attracting and retaining talent.
2026-04-16 03:09:52
Elutia has announced a $13.26 million registered direct offering, selling 3,175,000 shares of its Class A common stock at $3.40 per share and 725,000 prefunded warrants at $3.399 per warrant. The proceeds will be used for working capital and general corporate purposes. Lake Street Capital Markets is acting as the exclusive placement agent, with the offering expected to close around June 18, 2024.
2026-04-14 11:39:38
Elutia (ELUT) director Guido J. Neels received 6,250 shares of Class A Common Stock due to the vesting of restricted stock units (RSUs) on December 10, 2025. These shares were part of a 25,000 RSU grant that vests in four equal installments. Following this transaction, Neels directly owns 125,000 shares of Elutia's Class A Common Stock, with no cash involved in the transaction.
2026-04-03 10:10:23
Elutia Inc. has adopted its 2026 Inducement Award Plan, authorizing up to 2,000,000 shares of Class A common stock for new hires to attract, retain, and motivate talent without requiring shareholder approval under Nasdaq rules. The plan allows the Compensation Committee to administer various equity awards and includes change-in-control protections. Analysts currently rate ELUT stock as a Hold with a $1.00 price target, while TipRanks' AI Analyst assesses it as Neutral due to weak financial performance tempered by positive earnings call elements and technical support.
2026-03-28 20:10:13
Elutia Inc. (ELUT) faces a new ongoing risk of Nasdaq delisting despite recently regaining compliance with minimum bid price and market value standards. Failure to meet future Nasdaq criteria could lead to reduced trading liquidity, pressure on the share price, and hinder the company's ability to raise capital. Analysts currently project a significant upside potential for ELUT stock.
